Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials

Joseph F. Merola,[1] Alice B. Gottlieb,[2] Andreas Pinter,[3] Boni Elewski,[4] Melinda Gooderham,[5,6] Richard B. Warren,[7,8] Stefano Piaserico,[9] Krista Wixted,[10] Nancy Cross,[10] Nicola Tilt,[11] Susanne Wiegratz,[12] Ulrich Mrowietz[13]

[1]Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center, Dallas, TX, USA; [2]Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, NY, USA; [3]University Hospital Frankfurt, Frankfurt am Main, Germany; [4]Department of Dermatology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA; [5]SKiN Centre for Dermatology, Probity Medical Research, Peterborough, ON, Canada; [6]Department of Medicine, Queen's University, Kingston, ON, Canada; [7]Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK; [8]NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; [9]Dermatology Unit, Department of Medicine, Università di Padova, Padova, Italy; [10]UCB Pharma, Morrisville, NC, USA; [11]UCB Pharma, Slough, UK; [12]UCB Pharma, Monheim am Rhein, Germany; [13]Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Germany

Corresponding author:

Joseph F. Merola, MD M.MSc

Department of Dermatology

UT Southwestern Medical Center

5323 Harry Hines Blvd, Dallas, TX 75390, USA

+1 214-648-3111

Email: Joseph.Merola@UTSouthwestern.edu

Fig S1. Bimekizumab nail treatment example over 48 weeks from BE RADIANT



Previously presented at EADV 2021. Photos show the left-hand fingers and right thumb from one patient treated with bimekizumab (BKZ) every 4 weeks (Q4W)/every 8 weeks (Q8W) in BE RADIANT and included in this analysis, with the total modified Nail Psoriasis Severity Index (mNAPSI) shown at baseline and Week 48. BKZ: bimekizumab; mNAPSI: modified Nail Psoriasis Severity Index; Q4W: every 4 weeks; Q8W: every 8 weeks.

Table S1. Mean percent change from baseline in scalp, nail, or palmoplantar psoriasis over 2 years (OC)

	Scalp IGA ≥3 (N=821)		mNAPSI >10 (N=377)		Palmoplantar IGA ≥3 (N=193)	
OC; mean % change (SE)	BKZ total (N=821)	BKZ Q4W/Q8W (n=277)	BKZ total (N=377)	BKZ Q4W/Q8W (n=129)	BKZ total (N=193)	BKZ Q4W/Q8W (n=52)
Week 16	−92.2 (0.7)	−93.5 (1.1)	−64.5 (2.0)	−71.1 (2.7)	−92.6 (1.5)	−97.0 (1.3)
Year 1 (OLE Week 0[a])	−94.1 (0.7)	−96.3 (0.8)	−91.3 (1.1)	−93.2 (1.4)	−95.3 (1.2)	−97.6 (1.5)
OLE Week 24	−93.4 (0.7)	−95.3 (1.0)	−93.4 (0.9)	−94.8 (1.1)	−96.7 (1.1)	−95.3 (2.4)
Year 2 (OLE Week 48)	−93.4 (0.7)	−94.6 (1.2)	−91.5 (1.3)	−92.5 (1.7)	−96.2 (1.1)	−97.2 (1.4)

Scalp Investigator's Global Assessment (IGA) data are for patients with baseline scalp IGA ≥3, modified Nail Psoriasis Severity Index (mNAPSI) for patients with baseline mNAPSI >10, and palmoplantar IGA for patients with baseline palmoplantar IGA ≥3. Data are presented for patients with plaque psoriasis initially randomized to bimekizumab (BKZ) who later entered the open-label extension (OLE). Observed case (OC) was used for missing data. BKZ total consists of patients randomized to receive BKZ 320 mg every 4 weeks (Q4W) to Week 16, and who received either BKZ Q4W or every 8 weeks (Q8W) to the end of the first year (Week 48/52/56), and entered the OLE. BKZ Q4W/Q8W consists of patients randomized to BKZ 320 mg Q4W to Week 16, who received BKZ Q8W throughout the maintenance period and on OLE entry; there are no BE VIVID patients in this treatment arm. [a] OLE Week 0 corresponds to Week 48 for BE SURE, BE READY, and BE RADIANT, and Week 52 for BE VIVID. BKZ: bimekizumab; IGA: Investigator's Global Assessment; mNAPSI: modified Nail Psoriasis Severity Index; OC: observed case; OLE: open-label extension; Q4W: every 4 weeks; Q8W: every 8 weeks; SE: standard error.

Table S2. Complete clearance in scalp, nail, or palmoplantar psoriasis over 2 years (NRI)

	Scalp IGA ≥3 (N=821)		mNAPSI >10 (N=377)		Palmoplantar IGA ≥3 (N=193)	
Achievement of scalp IGA 0, mNAPSI 0, or palmoplantar IGA 0, n (%)	BKZ total (N=821)	BKZ Q4W/Q8W (n=277)	BKZ total (N=377)	BKZ Q4W/Q8W (n=129)	BKZ total (N=193)	BKZ Q4W/Q8W (n=52)
Week 16	681 (82.9)	239 (86.3)	85 (22.5)	39 (30.2)	167 (86.5)	47 (90.4)
Year 1 (OLE Week 0[a])	696 (84.8)	245 (88.4)	237 (62.9)	89 (69.0)	167 (86.5)	49 (94.2)
OLE Week 24	630 (76.7)	220 (79.4)	243 (64.5)	89 (69.0)	140 (72.5)	35 (67.3)
Year 2 (OLE Week 48)	643 (78.3)	230 (83.0)	246 (65.3)	87 (67.4)	151 (78.2)	43 (82.7)

Scalp Investigator's Global Assessment (IGA) 0 data are presented for patients with baseline scalp IGA ≥3, modified Nail Psoriasis Severity Index (mNAPSI) 0 for patients with baseline mNAPSI >10, and palmoplantar IGA 0 for patients with baseline palmoplantar IGA ≥3. Data are presented for patients with plaque psoriasis initially randomized to BKZ who later entered the open-label extension (OLE). Non-responder imputation (NRI) was used for missing data. BKZ total consists of patients randomized to receive BKZ 320 mg every 4 weeks (Q4W) to Week 16, and who received either BKZ Q4W or every 8 weeks (Q8W) to the end of the first year (Week 48/52/56), and entered the OLE. BKZ Q4W/Q8W consists of patients randomized to BKZ 320 mg Q4W to Week 16, who received BKZ Q8W throughout the maintenance period and on OLE entry; there are no BE VIVID patients in this treatment arm. [a] OLE Week 0 corresponds to Week 48 for BE SURE, BE READY, and BE RADIANT, and Week 52 for BE VIVID. BKZ: bimekizumab; IGA: Investigator's Global Assessment; mNAPSI: modified Nail Psoriasis Severity Index; NRI: non-responder imputation; OC: observed case; OLE: open-label extension; Q4W: every 4 weeks; Q8W: every 8 weeks.